NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00129935,EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer,https://clinicaltrials.gov/study/NCT00129935,,COMPLETED,"This is a prospective, randomised phase III trial, to compare the efficacy and safety profiles of two types of adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2) negative, node positive breast cancer patients.

Control Arm: This includes 4 cycles of EC 90/600 mg/m2 day 1 every 3 weeks, followed by 4 cycles of T 100 mg/m2 day 1 every 3 weeks.

Experimental Arm: This includes 4 cycles of ET 90/75 mg/m2, day 1 every 3 weeks, followed by 4 cycles of capecitabine 1250 mg/m2, twice a day, via oral intake, for 14 days, and then a one-week rest period.

Premenopausal women with hormone receptor positive tumours must receive 5 years of tamoxifen after the end of chemotherapy.

Postmenopausal women with hormone receptor positive tumours can receive tamoxifen or aromatase inhibitors (or both) after the end of chemotherapy.

Patients may receive radiotherapy when clinically indicated.",YES,Breast Cancer,DRUG: Docetaxel|DRUG: Capecitabine|DRUG: Epirubicin|DRUG: Cyclophosphamide,"Number of Participants With Disease-free Survival (DFS) Event, A participant was considered to have had a DFS event if there was evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason., 5 years","Number of Participants With Overall Survival (OS) Event, A participant was considered to have had a OS event if patient died from any cause., Up to 5 years|The Number of Participants Who Experienced Adverse Events (AE), Safety was assessed by standard clinical and laboratory tests, and were evaluated using NCI-CTC criteria v2.0, 5 years|Quality of Life Questionnaire: Number of Participants With Hair Loss, Hair loss was assessed by the quality of life of the patients through the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Breast Cancer 23 (EORTC QLQ-BR23) profile questionnaire, question 4. The quality of life of the patients was evaluated before each cycle and at the end of treatment.

In questionnaire, raw scores range from 0 to 100 and a high score represents a high level of functioning or Health Related Quality of Life, excluding single-item scales in which high scores represent a high level of symptoms. A difference of 10 points on the scale over baseline value was classified as the minimum clinically meaningful change in both questionnaires., Up to 24 months|Quality of Life Questionnaire: Number of Participants With Hair Loss Recovery, Hair Loss Recovery was assessed by a specific Hair Toxicity Questionnaire were patients answered if the hair was less abundant than before, weaker than before or other.

The questionnaire was evaluated up to two years after the end of chemotherapy., Up to 30 months|Quality of Life Questionnaire: Time to Taking Off the Wig, Time to taking off the wig was assessed by a specific Hair Toxicity Questionnaire were patients answered when they stop to use the wig.

The questionnaire was evaluated up to two years after the end of chemotherapy., Up to 30 months",,Spanish Breast Cancer Research Group,Sanofi|Hoffmann-La Roche|Pfizer,FEMALE,"ADULT, OLDER_ADULT",PHASE3,1384,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GEICAM 2003-10,2004-02,2013-06,2019-04-04,2005-08-12,2019-10-25,2023-03-31,"Hospital Arquitecto Marcide, Ferrol, A Coruña, 15405, Spain|Hospital General Universitario de Elche, Elche, Alicante, 03203, Spain|Hospital General Universitario de Elda, Elda, Alicante, 03600, Spain|Hospital Municipal de Badalona, Badalona, Barcelona, 08911, Spain|Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, 08916, Spain|Corporació Sanitaria Parc Taulí, Sabadell, Barcelona, 08208, Spain|Hospital del Espíritu Santo, Santa Coloma De Gramenet, Barcelona, 08923, Spain|Hospital Mutua de Terrassa, Terrassa, Barcelona, 08221, Spain|Consorci Sanitari de Terrassa, Terrassa, Barcelona, 08227, Spain|Hospital General Universitario de Vic, Vic, Barcelona, 08500, Spain|Hospital Universitario Marques de Valdecilla, Santander, Cantabria, 39008, Spain|Hospital Provincial de Castellón, Castellón De La Plana, Castellón, 12002, Spain|Hospital Universitario Reina Sofía, Córdoba, Cordoba, 14004, Spain|Hospital de Jerez de la Frontera, Jerez De La Frontera, Cádiz, 11407, Spain|Onkologikoa, Donostia-San Sebastián, Guipúzcoa, 20012, Spain|Hosptial Donostia, Donostia-San Sebastián, Guipúzcoa, 20014, Spain|Hospital de Barbastro, Barbastro, Huesca, 22300, Spain|Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, 28922, Spain|Hospital Universitario Severo Ochoa, Leganés, Madrid, 28911, Spain|Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, 28222, Spain|Hospital Universitario San Joan de Reus, Reus, Tarragona, 43201, Spain|Complejo Hospitalario Universitario A Coruña, A Coruña, 15006, Spain|Centro Oncológico de Galicia, A Coruña, 15009, Spain|Hospital General Universitario de Albacete, Albacete, 02066, Spain|Hospital General Universitario de Alicante, Alicante, 03010, Spain|Hospital Universitario Virgen de los Lirios, Alicante, 03804, Spain|Hospital del Mar, Barcelona, 08003, Spain|Hospital Universitario Santa Creu i Sant Pau, Barcelona, 08025, Spain|Hospital Clinic i Provincial, Barcelona, 08036, Spain|Hospital Universitario Puerta del Mar, Cádiz, 11009, Spain|Instituto Catalán de Oncología de Girona, Girona, 17007, Spain|Hospital Universitario Virgen de las Nieves, Granada, 18014, Spain|Hospital General Universitario de Guadalajara, Guadalajara, 19002, Spain|Complejo Hospitalario de Jaén, Jaén, 23007, Spain|Hospital Universitario Arnau de Vilanova de Lleida, Lleida, 25198, Spain|Hospital Universitario Lucus Augusti, Lugo, 27003, Spain|Hospital Universitario de la Princesa, Madrid, 28006, Spain|Hospital Universitario 12 de Octubre, Madrid, 28021, Spain|Hospital Universitario Ramón y Cajal, Madrid, 28034, Spain|Fundación Jiménez Díaz, Madrid, 28040, Spain|Hospital Clínico Universitario San Carlos, Madrid, 28040, Spain|Hospital General Universitario Morales Meseguer, Murcia, 30008, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, 30120, Spain|Hospital Clínico Universitario Virgen de la Victoria, Málaga, 29010, Spain|Hospital Regional Universitario Carlos Haya, Málaga, 29010, Spain|Complejo Hospitalario Unviersitario de Ourense, Ourense, 32005, Spain|Hospital Universitario de Salamanca, Salamanca, 37007, Spain|Hospital Universitario de Canarias, Santa Cruz De Tenerife, 38320, Spain|Hospital Universitario Virgen del Rocío, Sevilla, 41013, Spain|Hospital Universitario de Valme, Sevilla, 41014, Spain|Hospital Universitario La Fe, Valencia, 46009, Spain|Instituto Valenciano de Oncología, Valencia, 46009, Spain|Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain|Hospial General Universitario de Valencia, Valencia, 46014, Spain|Hospital Universitario Arnau de Vilanova de Valencia, Valencia, 46015, Spain|Hospital Provincial Rodríguez Chamorro de Zamora, Zamora, 49021, Spain|Hospital Clínico Universitario de Zaragoza ""Lozano Blesa"", Zaragoza, 50009, Spain|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain",
